Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Hyperfine concludes Contrast PMR study enrolment for Swoop MRI system
Hyperfine has completed patient enrolment in its multi-centre Contrast PMR study examining the use of contrast agents with the company’s …
-
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia. ARO-DIMER-PA …
-
Eli Lilly and QurCan sign genetic medicine deal
Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics …
-
BRAINBox and Prolight sign supply agreement for concussion tests
BRAINBox Solutions has signed an agreement with Prolight Diagnostics to secure the supply of Psyros instruments and cartridges, which will …
-
Taiho, Cullinan report improved PFS in Phase III NSCLC trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported results from the Phase III REZILIENT3 trial, showing that zipalertinib combined …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing …
-
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody, which …
-
J&J’s new reusable contact lens secures CE Mark
Johnson & Johnson (J&J) has received the CE Mark for its ACUVUE OASYS MAX 2-Week, a new reusable contact lens …
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process …
-
FDA grants 510(k) clearance to Emboliner system for TAVR procedures
Emboline has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Emboliner embolic protection system, intended …
-
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered …
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for …
-
Labcorp acquires MLM Medical Labs to expand global central lab network
Labcorp has acquired MLM Medical Labs, expanding its worldwide central laboratory and biomarker capabilities for clinical studies. MLM is a central …
-
BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM
Bristol Myers Squibb (BMS) has reported positive top-line results from the registrational Phase II QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; …
-
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RiboX Therapeutics’ investigational treatment …
